Logo

BeiGene Report Results of Brukinsa (zanubrutinib) in P-III ASPEN Study for Waldenström's Macroglobulinemia

Share this

BeiGene Report Results of Brukinsa (zanubrutinib) in P-III ASPEN Study for Waldenström's Macroglobulinemia

Shots:

  • The P-III APSEN study involve assessing of Brukinsa (zanubrutinib) vs AbbVie's Imbruvica (ibrutinib) in 229 patients with r/r or TN WM across 61 centers in the US- EU and Australia
  • The P-III APSEN study resulted in not meeting its 1EPs- i.e- superiority in CR & VGPR rate in up to 3yrs.; in r/r patients & overall patient population: VGPR rate (28.9% & 28.4% vs 19.8% & 19.2%); MRR (78.3% & 77.5% vs 80.2% & 77.8%); PFS @12mos. (92.4% & 85.9% vs 89.7% & 87.2%); OS @12mos. (98.8% & 92.5% vs 97.0% & 93.9%); safety profile were similar; respectively
  • Brukinsa (BGB-3111) is a BTK inhibitor- currently being evaluated in multiple clinical studies globally including China as a potential monothx. or in combination with other therapies targeting B cell malignancies

Click here ­to­ read full press release/ article | Ref: BeiGene | Image: USCA


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions